A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUPS STUDY ON EFFICACY AND SAFETY OF NAC 600 MG DAILY AND NAC 1200 MG DAILY AS MUCOLYTIC AGENT IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD EXACERBATION.

Trial Profile

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUPS STUDY ON EFFICACY AND SAFETY OF NAC 600 MG DAILY AND NAC 1200 MG DAILY AS MUCOLYTIC AGENT IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD EXACERBATION.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Acetylcysteine (Primary)
  • Indications Acute exacerbations of chronic bronchitis
  • Focus Therapeutic Use
  • Sponsors Zambon Company SpA
  • Most Recent Events

    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top